Adverum Biotechnologies, Inc (ADVM)

Etorro trading 970x250
Adverum Biotechnologies, Inc (ADVM) Logo

About Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Address: 800 Saginaw Drive, Redwood City, CA, United States, 94063

Adverum Biotechnologies, Inc News and around…

Latest news about Adverum Biotechnologies, Inc (ADVM) common stock and company :

Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer
06 Jan, 2022 Yahoo! Finance

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Star Seyedkazemi, Pharm.D., joined Adverum as the company’s chief development officer. Dr. Seyedkazemi will serve as a member of Adverum’s executive committee and will report to Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies. Dr. Seyedkaze

Chameleon Biosciences Appoints Silicon Valley Scientist and Entrepreneur, Dr. Thomas Chalberg, to Board Position
05 Jan, 2022 FinancialContent
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
04 Jan, 2022 Yahoo! Finance

- ADVM-062 is designed as a potential treatment for blue cone monochromacy (X-linked incomplete achromatopsia) -REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate being developed as a potentia

Adverum Biotechnologies (NASDAQ:ADVM) investors are sitting on a loss of 84% if they invested a year ago
01 Jan, 2022 Yahoo! Finance

It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try to...

Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
21 Dec, 2021 FinancialContent

Adverum Biotechnologies Inc(NASDAQ: ADVM)plans to conduct a Phase 2 trialof ADVM-022 in wet AMD at 2 X 10^11 vg/eye ...

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
21 Dec, 2021 Yahoo! Finance

- Finalizing Two-Dose Study Design for Phase 2 Trial of ADVM-022 in Wet AMDwith Intention to Dose First Patient in Q32022 - - Anticipates Near-term Hires to Further Strengthen Executive Team - - Board of Directors is Actively Pursuing the Addition of Two New Directors - - Expects Cash Position to Fund Development Plans and Operations into 2024 - REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting un

4 Short Squeeze Penny Stocks To Watch Right Now
13 Dec, 2021 FinancialContent
Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
06 Dec, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Rupert D’Souza, Ph.D., M.B.A., has joined Adverum as the company’s chief financial officer (CFO). Dr. D’Souza will serve as a member of Adverum’s executive committee and will report to Laurent Fischer M.D., president and chief executive officer at Adverum Biotechnologies. Dr. D’S

Moore Kuehn, PLLC Encourages Investors of Adverum Biotechnologies, Inc. to Contact Law Firm
30 Nov, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own ADVM please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone a

Here's What Adverum Biotechnologies, Inc.'s (NASDAQ:ADVM) Shareholder Ownership Structure Looks Like
17 Nov, 2021 Yahoo! Finance

If you want to know who really controls Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ), then you'll have to look at the...

Adverum Reports Third Quarter 2021 Results
04 Nov, 2021 Yahoo! Finance

REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the third quarter ending September 30, 2021 and provided a business update. “Last month we presented new data at scientific meetings from both our OPTIC and INFINITY studies which reinforce our plans to focus the development of ADVM-022 in wet age-related macular

First Week of ADVM November 19th Options Trading
01 Nov, 2021 FinancialContent

Investors in Adverum Biotechnologies Inc (ADVM) saw new options begin trading this week, for the November 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADVM options chain for the new November 19th contracts and identified the following call contract of particular interest.

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
10 Oct, 2021 FinancialContent
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
09 Oct, 2021 Yahoo! Finance

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- Marked Differences in Intraocular Pressure in Patients with DME Versus Wet AMD, and High 6 x 10^11 vg/eye Dose Versus Low 2 x 10^11 vg/eye Dose Marked Differences in Intraocular Pressure in Patients with DME Versus Wet AMD, and High 6 x 10^11 vg/eye Dose Versus Low 2 x 10^11 vg/eye Dose REDWOOD CITY, Calif., Oct. 09, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gen

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

44 Biggest Movers From Yesterday
05 Oct, 2021 FinancialContent

Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced ...

Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher
04 Oct, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded down 1.09% to 33,951.17 while the NASDAQ fell 2.28% to 14,234.17. The S&P also ...

12 Health Care Stocks Moving In Monday's Intraday Session
04 Oct, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading ...

30 Stocks Moving In Monday's Mid-Day Session
04 Oct, 2021 FinancialContent

Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
04 Oct, 2021 FinancialContent

Gainers OpGen (NASDAQ:OPGN) shares moved upwards by 30.07% to $3.59 during Monday's pre-market session. The market ...

18 Stocks Moving in Monday's Pre-Market Session
04 Oct, 2021 FinancialContent

Gainers CohBar, Inc. (NASDAQ: CWBR) rose 22.8% to $1.13 in pre-market trading after dropping over 4% on Friday. Farmmi, Inc.. ...

Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety
04 Oct, 2021 FinancialContent

Adverum Biotechnologies Inc(NASDAQ: ADVM)announced new long-term datafrom the OPTIC trial of ADVM-022 gene therapy ...

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
03 Oct, 2021 FinancialContent

Biotech stocks came under pressure in the week endingOct. 1, dragged by broader market weakness and the selling ofvaccine ...

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
03 Oct, 2021 FinancialContent
Companies Like Adverum Biotechnologies (NASDAQ:ADVM) Are In A Position To Invest In Growth
03 Oct, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
01 Oct, 2021 Yahoo! Finance

-- Results featured in a presentation today at the Retina Society’s 54th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years -- -- Over 80% reduction in annualized anti-VEGF injection frequency at 2 x 10^11 vg/eye -- -- More than half of patients free of injection at median follow-up of 1.7 years at 2 x 10^11 vg/eye -- REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy com

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
27 Sep, 2021 FinancialContent
How The Parts Add Up: VHT Headed For $289
23 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $289.42 per unit.

Adverum Biotechnologies, Inc (ADVM) is a NASDAQ Common Stock listed in , ,

970x250